Guest: Dr. Elizabeth Baerg Hall
Host: Dr. Chris Morrow
Producer: Craig Ferguson
Music: "Stand With Me" by Adrian Walther licensed via SoundStripe

Episode Timestamps
• [00:00] - Introduction and episode overview
• [02:03] - Life transitions and when ADHD becomes visible in adults
• [04:14] - How ADHD can be masked by structure and support systems
• [05:21] - Red flags for ADHD in primary care settings
• [08:54] - Who can diagnose ADHD and what tools are available
• [12:05] - The importance of impairment in diagnosis and avoiding overdiagnosis
• [16:36] - Common comorbidities: Anxiety, depression, and bipolar disorder
• [19:39] - ADHD and substance use disorder
• [21:26] - Barriers to diagnosis and treatment: Stigma and misconceptions about stimulants
• [24:07] - Inequities in access to care, including Indigenous patients
• [26:26] - Challenges for rural patients and older adults with ADHD
• [29:00] - Resources and support in BC: CADRA, Shared Care, and Skills for Success
• [30:56] - ADHD pathways and UBC CPD educational opportunities
• [32:59] - Closing remarks and conference information
• [33:52] - Knowledge nugget: The history of psychostimulants

Studies & Research Mentioned
• CADDRA – Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines, 4.1 Edition. Toronto, ON: CADDRA; 2020. Accessed January 13, 2026. https://adhdlearn.caddra.ca/wp-content/uploads/2022/08/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf
• Centers for Disease Control and Prevention. Diagnosing ADHD. Updated 2024. Accessed January 13, 2026. https://www.cdc.gov/adhd/diagnosis/index.html
• The MTA Cooperative Group: A 14-Month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD) . Arch Gen Psychiatry 1999;56:1073-1086.
• The MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 1999;56:1088-1096.
• Molina BSG, Kipp HL, Joseph HM, et al. Stimulant Diversion Risk Among College Students Treated for ADHD: Primary Care Provider Prevention Training. Acad Pediatr. 2020;20(1):119-127. doi:10.1016/j.acap.2019.06.002
• National Institute of Mental Health. The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study (MTA): Questions and Answers. Revised November 2009. National Institute of Mental Health website. Accessed January 13, 2026. https://www.nimh.nih.gov/funding/clinical-research/practical/mta/the-multimodal-treatment-of-attention-deficit-hyperactivity-disorder-study-mtaquestions-and-answers
• Ramtekkar UP, Reiersen AM, Todorov AA, Todd RD. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010;49(3):217-28.e283.

(C) 2025 UBC Medicine Learning Network

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Endocrinologist Dr. Jordanna Kapeluto unpacks the evolving science of obesity and the role of GLP-1 medications like semaglutide. We explore obesity as a complex, chronic disease, the impact of weight bias in health care, and the promise and pitfalls of new treatments. From mechanisms of action to real-world outcomes, this conversation challenges assumptions and highlights the importance of compassionate, evidence-based care.   

Host: Dr. Chris Morrow

Producer:  Craig Ferguson

Music: "Stand With Me" by Adrian Walther licensed via SoundStripe

(C) 2025 UBC Medicine Learning Network

Episode Timestamps

[00:00] - Introduction and episode overview

[01:38] - Medical diagnosis of obesity: Why it is important to diagnose and treat

[02:27] - Evolution of our understanding of obesity and weight dynamics

[04:30] - Stigma surrounding obesity and patient experiences of weight bias affecting access to appropriate care or diagnostics

[06:14] - Defining and diagnosing obesity

[12:40] - Discussion on GLP-1 agonists

[15:45] - GLP-1 agonists and weight loss

[18:14] - GLP-1s in diabetes treatment

[18:42] - Criteria for using GLP-1s as a weight loss agent

[22:05] - GLP-1s: Downsides and barriers

[26:50] - Guidance for primary care providers on prescribing GPL-1s

[30:27] - Closing thoughts from Dr. Jordanna Kapeluto

[31:50] - Closing remarks from Dr. Chris Morrow on GLP-1 agonists

Studies & Research Mentioned

Rubino F, Bartolomucci A, Buse JB, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;S2213-8587(24)00316-4. doi:10.1016/S2213-8587(24)00316-4

Palmer AB, Roshani R, McCormick JB, Fisher-Hoch SP, Below JE, North KE, Gordon-Larsen P. Excess Adiposity Without Obesity in a High-Risk Population. JAMA Netw Open. 2025 Oct 1;8(10):e2535194. doi: 10.1001/jamanetworkopen.2025.35194. PMID: 41042515; PMCID: PMC12495492.Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest. 2024;134(2):e175634. Published 2024 Jan 16. doi:10.1172/JCI175634 

Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-7405.

Quetelet A. Sur l'homme et le développement de ses facultés, ou Essai de physique sociale [A Treatise on Man and the Development of His Faculties]. Bachelier; 1835.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How is AI reshaping the future of clinical medicine? In this episode, we explore the transformative power of generative AI in healthcare with Dr. Sofia Valanci, Physician Program Advisor at the Royal College of Physicians and Surgeons of Canada. Dr. Valanci shares insights on using AI to address diagnostic uncertainty, ethical concerns when using AI for scribing, protecting patient privacy and confidentiality, the impacts of AI on planetary health, and the importance of AI literacy and education in clinical practice.

DISCLAIMER: The views expressed in this podcast are those of the speakers and do not necessarily reflect the official policy or position of UBC or the Faculty of Medicine.

Host: Dr. Chris Morrow

Producer:  Craig Ferguson

Music: "Stand With Me" by Adrian Walther licensed via SoundStripe

(C) 2025 UBC Medicine Learning Network

Episode Timestamps

[00:00] – Introduction and episode overview

[02:08] – Generative AI and how it applies to clinical medicine

[03:19] – Are clinical applications of AI effective and safe?

[05:06] – How AI is being used in clinical medicine today

[06:56] – AI scribes - what are we learning about it and how is it being received?

[10:27] – AI and why detailed prompts, context, and tone matter

[14:09] – AI hallucinations and outputs

[15:25] – Effectiveness of AI in patient education and medical literature

[17:17] – Ethical concerns and issues

[17:57] – Planetary health impacts

[18:49] – Protecting patient privacy and confidentiality

[21:39] – Navigating incorrect AI-generated patient diagnoses

[22:29] – Getting started with AI and practical tips for clinicians

[23:58] – Closing thoughts

Resources & References

Studies & Research Mentioned

Li P, Yang J, Islam MA, Ren S. Making AI less "thirsty": uncovering and addressing the secret water footprint of AI models. arXiv. Published online April 6, 2023. doi:10.48550/arXiv.2304.03271  

Doctors of BC. Reducing physician burdens: AI Scribes Pilot results. Doctors of BC website. https://www.doctorsofbc.ca/technology-digital-health/2025/reducing-physician-burdens-ai-scribes-pilot-results. Published2025. Accessed November 4, 2025.

Rajpurkar P, Irvin J, Ball RL, et al. Deep learning for chest radiograph diagnosis: a retrospective comparison of the CheXNeXt algorithm to practicing radiologists. PLoS Med. 2018;15(11):e1002686. doi:10.1371/journal.pmed.1002686

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.